Archive
1319 articles, sorted by publication time.
AL050 aims to address two challenges at once: insufficient enzyme activity and delivery to the brain. The global license brings resources for development, but whether it can clear accumulated lipids and thereby slow the disease remains a question for human studies.
Covering more serotypes also requires maintaining immune responses. Vaxcyte announced pivotal trial results involving more than four thousand adults, but two serotypes still fell short of the stricter threshold in individual comparisons with Capvaxive. Whether the vaccine can secure approval will depend on additional evidence.
Can combining two ways of regulating vascular signaling in a single antibody deliver more lasting improvements to a damaged retina? Surrozen’s new drug is set to undergo early human testing, with a comparison against an existing therapy included in the trial design.
From light-sensitive proteins in single-celled algae to experimental tools that precisely control neurons, optogenetics allows scientists to test causal relationships between brain circuits and behavior. Three pioneers share the Nobel Prize, highlighting the long path from basic discoveries to medical applications.
Intensive care units need to keep pace with changing immune responses, while cardiovascular care needs understandable AI judgments. Two newly funded projects will explore personalized treatment and continuous oversight, respectively; whether they can improve patient outcomes still requires experimental and clinical testing.
A new analysis from the FORTIFY trial shows that markers of heart muscle injury returned to the normal range in some patients, with favorable signals also seen in cardiac pumping function. But the small sample and exploratory statistics leave these findings some way from establishing long-term cardiac protection.
An antibody targeting inflammation and fibrosis has secured backing from a major pharmaceutical company and will move toward larger clinical trials. The partnership funding paves the way for development, but early signs of improved organ function remain some distance from proving that the treatment can prevent disease progression.
For patients with platinum-resistant ovarian cancer who have received multiple lines of treatment, a novel antibody-drug conjugate offers evidence of sustained tumor control; whether it outperforms existing therapies, and how efficacy and side effects should be weighed, remain to be clarified in randomized trials.
Moving from a protein sequence to a usable drug still involves a series of experimental hurdles. This collaboration connects AI design with BioMarin’s enzyme therapy development process, first seeking candidate molecules with suitable activity and stability, then assessing whether they can advance to preclinical testing.
Can spectra obtained with a handheld probe help physicians determine which skin lesions need a biopsy? An ex vivo tissue study offers preliminary clues, but identifying cancer types and validating performance in clinical practice remain the next hurdles.
Letting AI handle only cases it is more confident about may be one path toward autonomous diagnosis. But when more than half of cases are handed back to physicians, whether the entire workflow can improve care remains unanswered.
Using a natural compound as a starting point, the research team screened approximately 12 million molecules for candidates, then validated their activity through synthesis and enzyme experiments. The findings provide a new starting point for intervening in pathways involved in bacterial pathogenicity and antibiotic resistance, but several hurdles remain before they can lead to treatments for infectious diseases.